Hybrid Membrane-Camouflaged Biomimetic Immunomodulatory Nanoturrets with Sequential Multidrug Release for Potentiating T Cell-Mediated Anticancer Immunity
Journal of the American Chemical Society · 10.07.2024 · 146 (27) · 18592-18605
DOI: 10.1021/jacs.4c04840 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 29.06.2024. Verfasst von Wenjing Yao und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and…. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Ascorbic Acid, T-Lymphocytes, Antineoplastic Agents. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: China Pharmaceutical University, Natural Science Foundation of Jiangsu Province, Government of Jiangsu Province.
Abstract (Originalsprache)
Ascorbic acid (AA) has been attracting great attention with its emerging potential in T cell-dependent antitumor immunity. However, premature blood clearance and immunologically "cold" tumors severely compromise its immunotherapeutic outcomes. As such, the reversal of the immunosuppressive tumor microenvironment (TME) has been the premise for improving the effectiveness of AA-based immunotherapy, which hinges upon advanced AA delivery and amplified immune-activating strategies. Herein, a novel Escherichia coli (E. coli) outer membrane vesicle (OMV)-red blood cell (RBC) hybrid membrane (ERm)-camouflaged immunomodulatory nanoturret is meticulously designed based on gating of an AA-immobilized metal-organic framework (MOF) onto bortezomib (BTZ)-loaded magnesium-doped mesoporous silica (MMS) nanovehicles, which can realize immune landscape remodeling by chemotherapy-assisted ascorbate-mediated immunotherapy (CAMIT). Once reaching the acidic TME, the acidity-sensitive MOF gatekeeper and MMS core within the nanoturret undergo stepwise degradation, allowing for tumor-selective sequential release of AA and BTZ. The released BTZ can evoke robust immunogenic cell death (ICD), synergistically promote dendritic cell (DC) maturation in combination with OMV, and ultimately increase T cell tumor infiltration together with Mg2+. The army of T cells is further activated by AA, exhibiting remarkable antitumor and antimetastasis performance. Moreover, the CD8-deficient mice model discloses the T cell-dependent immune mechanism of the AA-based CAMIT strategy. In addition to providing a multifunctional biomimetic hybrid nanovehicle, this study is also anticipated to establish a new immunomodulatory fortification strategy based on the multicomponent-driven nanoturret for highly efficient T cell-activation-enhanced synergistic AA immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, People…
- Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, People's Republic…
- Pancreas Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, People's Republic of China.
- Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430022, People's Republic of China.
- Department of Radiology, Yingshan People's Hospital, Huanggang, Hubei 438700, People's Republic of China.
ORCID-Profile: Shenghong Ju, Wenpei Fan
Förderung
- China Pharmaceutical University
- Natural Science Foundation of Jiangsu Province
- Government of Jiangsu Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Zhongnan Hospital of Wuhan University
- Zhongda Hospital of Southeast University
Zitieren
APA
Yao, W., Liu, W., Su, F., Wang, J., Li, H., Sun, M., Ma, Y., Xu, Y., Li, D., Wang, Y., Lu, N., Ju, S., & Fan, W. (2024). Hybrid Membrane-Camouflaged Biomimetic Immunomodulatory Nanoturrets with Sequential Multidrug Release for Potentiating T Cell-Mediated Anticancer Immunity. Journal of the American Chemical Society, 146(27), 18592-18605. https://doi.org/10.1021/jacs.4c04840
Vancouver
Yao W, Liu W, Su F, Wang J, Li H, Sun M, et al. Hybrid Membrane-Camouflaged Biomimetic Immunomodulatory Nanoturrets with Sequential Multidrug Release for Potentiating T Cell-Mediated Anticancer Immunity. Journal of the American Chemical Society. 2024;146(27):18592-18605. doi:10.1021/jacs.4c04840
BibTeX
@article{Yao2024,
author = {Yao, Wenjing and Liu, Weiwei and Su, Fanshu and Wang, Junran and Li, Hao and Sun, Minghao and Ma, Yuanyuan and Xu, Yingjie and Li, Danrui and Wang, Yazhou and Lu, Nan and Ju, Shenghong and Fan, Wenpei},
title = {Hybrid Membrane-Camouflaged Biomimetic Immunomodulatory Nanoturrets with Sequential Multidrug Release for Potentiating T Cell-Mediated Anticancer Immunity},
journal = {Journal of the American Chemical Society},
year = {2024},
volume = {146},
number = {27},
pages = {18592--18605},
doi = {10.1021/jacs.4c04840}
}
EUVIMED